Stay updated with breaking news from Alter Pharma Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million (€0.2 million in 2020) Significant expansion of commercial footprint of Maxigesic
Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million Significant expansion of commercial footprint of Maxigesic® IV ... | March 16, 2022
Investegate announcements from Hyloris Pharmaceuticals SA, Correcting -- Hyloris reports results for the full year 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth ...